Tom Rabinowitz

Tom Rabinowitz

Auto-generated profile, based on publicly available information

Tom Rabinowitz

Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LMLiron Malki
Liron Malki
OSOfer Sarig
Ofer Sarig
MRMaria-Teresa Romano
Maria-Teresa Romano
MMMarie-Claire Méchin
Marie-Claire Méchin
APAlon Peled
Alon Peled
ESEli Sprecher
Eli Sprecher
Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia among women of African ancestry. The disease is occasionally observed to affect women in families in a manner that suggests an autosomal dominant trait and usually manifests clinically after intense hair grooming. We sought to determine whether there exists a genetic basis of CCCA and, if so, what it is. We used exome sequencing in a group of women with alopecia (discovery set), compared the results with those in a public repository, and applied other filtering criteria to identify candidate genes. We then performed direct sequencing to identify disease-associated DNA variations and RNA sequencing, protein modeling, immunofluorescence staining, immunoblotting, and an enzymatic assay to evaluate the consequences of potential etiologic mutations. We used a replication set that consisted of women with CCCA to confirm the data obtained with the discovery set. In the discovery set, which included 16 patients, we identified one splice site and three heterozygous missense mutations in PADI3 in 5 patients (31%). (The approximate prevalence of the disease is up to 5.6%.) PADI3 encodes peptidyl arginine deiminase, type III (PADI3), an enzyme that post-translationally modifies other proteins that are essential to hair-shaft formation. All three CCCA-associated missense mutations in PADI3 affect highly conserved residues and are predicted to be pathogenic; protein modeling suggests that they result in protein misfolding. These mutations were found to result in reduced PADI3 expression, abnormal intracellular localization of the protein, and decreased enzymatic activity — findings that support their pathogenicity. Immunofluorescence staining showed decreased expression of PADI3 in biopsy samples of scalp skin obtained from patients with CCCA. We then directly sequenced PADI3 in an additional 42 patients (replication set) and observed genetic variants in 9 of them. A post hoc analysis of the combined data sets showed that the prevalence of PADI3 mutation was higher among patients with CCCA than in a control cohort of women of African ancestry (P=0.002 by the chi-square test; P=0.006 by Fisher’s exact test; and after adjustment for relatedness of persons, P=0.03 and P=0.04, respectively). Mutations in PADI3, which encodes a protein that is essential to proper hair-shaft formation, were associated with CCCA. (Funded by the Ram Family Foundation and others.)

1 August 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JMJanan Mohamad
Janan Mohamad
OSOfer Sarig
Ofer Sarig
LGLisa M. Godsel
Lisa M. Godsel
APAlon Peled
Alon Peled
NMNatalia Malchin
Natalia Malchin
ESEli Sprecher
Eli Sprecher

20 February 2019 in Genome Research
Verified
Journal Article
Open access
PDF file
TRTom Rabinowitz
Tom Rabinowitz
APAvital Polsky
Avital Polsky
DGDavid Golan
David Golan
ADArtem Danilevsky
Artem Danilevsky
GSGuy Shapira
Guy Shapira
NSNoam Shomron
Noam Shomron
In the last decade, noninvasive prenatal diagnosis (NIPD) has emerged as an effective procedure for early detection of inherited diseases during pregnancy. This technique is based on using cell-free DNA (cfDNA) and fetal cfDNA (cffDNA) in maternal blood, and hence, has minimal risk for the mother and fetus compared with invasive techniques. NIPD is currently used for identifying chromosomal abnormalities (in some instances) and for single-gene disorders (SGDs) of paternal origin. However, for SGDs of maternal origin, sensitivity poses a challenge that limits the testing to one genetic disorder at a time. Here, we present a Bayesian method for the NIPD of monogenic diseases that is independent of the mode of inheritance and parental origin. Furthermore, we show that accounting for differences in the length distribution of fetal- and maternal-derived cfDNA fragments results in increased accuracy. Our model is the first to predict inherited insertions–deletions (indels). The method described can serve as a general framework for the NIPD of SGDs; this will facilitate easy integration of further improvements. One such improvement that is presented in the current study is a machine learning model that corrects errors based on patterns found in previously processed data. Overall, we show that next-generation sequencing (NGS) can be used for the NIPD of a wide range of monogenic diseases, simultaneously. We believe that our study will lead to the achievement of a comprehensive NIPD for monogenic diseases.

1 January 2020 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
TRTom Rabinowitz
Tom Rabinowitz
NSNoam Shomron
Noam Shomron
Noninvasive prenatal diagnosis (NIPD) is a risk-free alternative to invasive methods for prenatal diagnosis, e.g. amniocentesis. NIPD is based on the presence of fetal DNA within the mother’s plasma cell-free DNA (cfDNA). Though currently available for various monogenic diseases through detection of point mutations, NIPD is limited to detecting one mutation or up to several genes simultaneously. Noninvasive prenatal whole exome/genome sequencing (WES/WGS) has demonstrated genome-wide detection of fetal point mutations in a few studies. However, Genome-wide NIPD of monogenic disorders currently has several challenges and limitations, mainly due to the small amounts of cfDNA and fetal-derived fragments, and the deep coverage required. Several approaches have been suggested for addressing these hurdles, based on various technologies and algorithms. The first relevant software tool, Hoobari, recently became available. Here we review the approaches proposed and the paths required to make genome-wide monogenic NIPD widely available in the clinic.

1 November 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JMJanan Mohamad
Janan Mohamad
OSOfer Sarig
Ofer Sarig
LMLiron Malki
Liron Malki
TRTom Rabinowitz
Tom Rabinowitz
SASari Assaf
Sari Assaf
ESEli Sprecher
Eli Sprecher

31 March 2021 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JMJanan Mohamad
Janan Mohamad
LSLiat Samuelov
Liat Samuelov
NMNatalia Malchin
Natalia Malchin
TRTom Rabinowitz
Tom Rabinowitz
SASari Assaf
Sari Assaf
OSOfer Sarig
Ofer Sarig